Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS improvements, addressing a high unmet need in platinum-resistant ovarian ...

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...

Pembrolizumab combined with weekly paclitaxel ± bevacizumab reduced death risk by 18% and improved median OS by 3.7 months versus paclitaxel ± bevacizumab in all comers. Progression-free survival ...

Merck MRK is focusing on driving its long-term growth with its new products and a promising set of pipeline candidates as its blockbuster PD-L1 inhibitor, Keytruda, faces patent expiration in 2028.